The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro

The very low density lipoprotein receptor (VLDLr) binds diverse ligands, including urokinase-type plasminogen activator (uPA) and uPA-plasminogen activator inhibitor-1 (PAI-1) complex. In this study, we characterized the effects of the VLDLr on the internalization, catabolism, and function of the uPA receptor (uPAR) in MCF-7 and MDA-MB-435 breast cancer cells. When challenged with uPA . PAI-1 complex, MDA-MB-435 cells internalized uPAR; this process was inhibited by 80% when the activity of the VLDLr was neutralized with receptor-associated protein (RAP), To determine whether internalized uPAR is degraded, we studied the catabolism of [S-35]methionine-labeled uPAR. In the absence of exogenous agents, the uPAR catabolism t(1/2) was 8.2 h. uPA . PAI-1 complex accelerated uPAR catabolism (t(1/2) to 1.8 h), while RAP inhibited uPAR catabolism in the presence (t(1/2) of 7.8 h) and absence (t(1/2) of 16.9 h) of uPA . PAI-1 complex, demonstrating a critical role for the VLDLr, When MCF-7 cells were cultured in RAP, cell surface uPAR levels increased gradually, reaching a new steady-state in 3 days, The amount of uPA which accumulated in the medium also increased. Culturing in RAP for 3 days increased MCF-7 cell motility by 2.2 +/- 0.1-fold and by 4.4 +/- 0.3-fold when 1.0 nm uPA was added. The effects of RAP on MCF-7 cell motility were entirely abrogated by an antibody which binds uPA and prevents uPA binding to uPAR. MCF-7 cells that were cultured in RAP demonstrated increased levels of activated mitogen-activated protein kinases, Furthermore, the MEK inhibitor, PD098059, decreased the motility of RAP-treated cells without affecting control cultures. These studies suggest a model in which the VLDLr regulates autocrine uPAR-initiated signaling and thereby regulates cellular motility.